Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : American Bio Medica (ABMC) drug test solution -taking off! -- Ignore unavailable to you. Want to Upgrade?

To: John Anderfuren who wrote (562)	11/2/1999 10:28:00 AM
From: Skywatcher	Read Replies (2) \| Respond to of 629

U.S. Patent Office Awards Utility Patent to American Bio Medica KINDERHOOK, N.Y.--(BUSINESS WIRE)--Nov. 2,1999--American Bio Medica Corp. (Nasdaq:ABMC - news) today announced that the U.S. Patent Office issued a utility patent for the Company's Rapid Drug Screen(tm) family of on-site tests for substances of abuse. ''This utility patent is a tremendous addition to our portfolio of international patents and trademarks because it is directed at important features of our Rapid Drug Screen drug test kit and thus provides even more protection for our unique, single-step testing products,'' commented ABMC Chairman and CEO Stan Cipkowski. The utility patent covers the Rapid Drug Screen drug test kit in which the testing card is inserted through a security-sealed slit in the lid of the sample cup. This distinguishes ABMC's test from other products on the market that require the test administrator to add reagents, use a pipette to transfer the urine sample or mix, tilt or stir the mixture. The Company explained that its newly patented utility feature confirms the Rapid Drug Screen as the safest on-site drug test commercially available, since competitive products introduce the possibility for exposure of the test administrator to the urine specimen. ''With our new utility patent, we are in an even better position to address and deal with copycat products,'' added Cipkowski. ''This strengthens our existing patent infringement and trademark dilution cases, and enables us to pursue firms that are infringing upon our utility patent. Ultimately, eliminating infringement will strengthen our industry presence and allow ABMC to capitalize upon its competitive testing advantages.'' The Rapid Drug Screen single-step tests for substances of abuse generate results in five minutes and are unrivaled for ease of use. The most secure and flexible total testing system on the market, ABMC's on-site tests simultaneously screen for the presence or absence of up to nine illicit drugs. chris